scholarly journals Peptides Regulate Cortical Thymocytes Differentiation, Proliferation, and Apoptosis

2011 ◽  
Vol 2011 ◽  
pp. 1-5 ◽  
Author(s):  
V. Kh. Khavinson ◽  
V. O. Polyakova ◽  
N. S. Linkova ◽  
A. V. Dudkov ◽  
I. M. Kvetnoy

The processes of differentiation, proliferation, and apoptosis were studied in a cell culture of human cortical thymocytes under the influence of short peptides T-32 (Glu-Asp-Ala) and T-38 (Lys-Glu-Asp). Peptides T-32 and T-38 amplified cortical thymocytes differentiation towards regulatory T cells, increased their proliferative activity, and decreased the level of apoptosis. Moreover, peptides under study stimulated proliferative and antiapoptotic activity of the mature regulatory T cells.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e22129-e22129
Author(s):  
Simona Partlova ◽  
Anna Fialova ◽  
Ludek Sojka ◽  
Lukas Rob ◽  
Jirina Bartunkova ◽  
...  

e22129 Background: Ovarian cancer is diagnosed in more than 190,000 new patients every year and is known to have the highest mortality rate among gynaecologic cancers. The type of immune cells that are present within the tumor microenvironment can play a crucial role in the survival of patients. However, little is known about the dynamics of the tumor-infiltrating immune cells during disease progression. Methods: We studied the immune cells infiltrating the tumor tissue of ovarian cancer patients at different stages of disease. We analysed the patterns of T lymphocytes in fresh tumor tissue as well as blood samples of 44 newly diagnosed ovarian cancer patients by flow cytometry. To evaluate whether regulatory T cells (Tregs) develop in situ or migrate to tumor tissue, we measured a concentration of chemokine CCL22 in tumor cell culture supernatants. We also determined the expression of CCR4 on circulating as well as tumor-infiltrating Tregs by flow cytometry. Results: The early stages of development of ovarian carcinomas were characterized by a strong Th17 immune response, whereas in stage II patients, recruitment of high numbers of Th1 cells was observed. In disseminated tumors (stage III-IV), we detected a dominant population of Helios+ activated regulatory T cells along with high numbers of macrophages and immature myeloid dendritic cells. Tumor-infiltrating Tregs had markedly lower expression of CCR4 than circulating Tregs, and the numbers of tumor-infiltrating Tregs significantly correlated with the levels of CCL22 in ovarian tumor cell culture supernatants, suggesting their recruitment via a CCR4/CCL22 interaction. CCL22 was mainly produced by tumor cells, macrophages and mDCs in the primary ovarian tumors, and its expression markedly increased in response to IFNgamma. Conclusions: Taken together, the specific recruitment of Tregs, probably triggered by inflammatory stimuli, leads to a significant immune suppression in the advanced stages of ovarian cancer.


2021 ◽  
Vol 6 (61) ◽  
pp. eabe4723
Author(s):  
Steffie Junius ◽  
Adamantios V. Mavrogiannis ◽  
Pierre Lemaitre ◽  
Margaux Gerbaux ◽  
Frederik Staels ◽  
...  

Regulatory T cells (Tregs) are indispensable for the control of immune homeostasis and have clinical potential as a cell therapy for treating autoimmunity. Tregs can lose expression of the lineage-defining Foxp3 transcription factor and acquire effector T cell (Teff) characteristics, a process referred to as Treg plasticity. The extent and reversibility of such plasticity during immune responses remain unknown. Here, using a murine genetic fate-mapping system, we show that Treg stability is maintained even during exposure to a complex microbial/antigenic environment. Furthermore, we demonstrate that the observed plasticity of Tregs after adoptive transfer into a lymphopenic environment is a property limited to only a subset of the Treg population, with the nonconverting majority of Tregs being resistant to plasticity upon secondary stability challenge. The unstable Treg fraction is a complex mixture of phenotypically distinct Tregs, enriched for naïve and neuropilin-1–negative Tregs, and includes peripherally induced Tregs and recent thymic emigrant Tregs. These results suggest that a “purging” process can be used to purify stable Tregs that are capable of robust fate retention, with potential implications for improving cell transfer therapy.


2013 ◽  
Vol 22 (19) ◽  
pp. 2596-2605 ◽  
Author(s):  
Tom Erkers ◽  
Silvia Nava ◽  
Jena Yosef ◽  
Olle Ringdén ◽  
Helen Kaipe

Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 2941-2941
Author(s):  
Jose Caetano Villasboas B. ◽  
Stephen Ansell

Abstract BACKGROUND Diffuse large B-cell lymphoma (DLBCL) is a high-grade malignancy and the most common subtype of lymphoma worldwide. Standard therapy with anthracycline-based chemotherapy and rituximab is able to cure about two thirds of patients but a significant proportion will develop relapsed/refractory disease. Salvage treatment options in this setting are limited and only effective in a minority of patients. Most of these patients will eventually die from progressive disease, underscoring the pressing clinical need for the development of new treatment strategies. Checkpoint blockade therapy has demonstrated efficacy in a variety of cancers and involves modulating the host's immune response towards an effective anti-tumoral attack. Trials using programmed cell death protein 1 (PD-1) blockers in advanced hematological malignancies demonstrated remarkable activity in patients with Hodgkin lymphoma. Unfortunately, results in DLBCL were marginal and short lived. The mechanisms underlying the failure of immune checkpoint blockade in DLBCL are not known. To better understand mechanisms of immune evasion we utilized mass cytometry to the study of immune subsets in the tumor microenvironment (TME) of DLBCL. METHODS Viably cryopreserved cell suspensions created from clinical specimens of patients with DLBCL were obtained from our biorepository. Specimens were stained using a cocktail of metal-tagged antibodies recognizing over 32 surface proteins and acquired on the mass cytometer (CyTOF2™, Fluidigm). Control tissue consisted of reactive lymph node (LN) tissue, tonsil and spleen, obtained from patients without diagnosis of cancer. Analysis was performed using Cytobank (www.cytobank.com). Institutional Review Board approved the conduct of this study. RESULTS Thirteen patient samples were available for analysis (7 DLBCL, 6 controls). DLBCL samples originated from LN (4), spleen (2), and adrenal gland (1). Control tissue consisted of tonsil (3), reactive LN (2), and normal spleen (1). Global analysis of CD45+ cells showed that T-cells were more commonly found in the TME of DLBCL than controls (DLBCL 47.2% vs. 24.5% in controls; Figure 1). The difference persisted when the analysis was restricted to LN specimens (50.2% in DLBCL vs. 25.1% in normal LN). On both DLBCL and control samples the majority of T-cells were CD4+ (61.1% in DLBCL; 75.3% in control) compared to CD8+ T-cells (33.3% in DLBCL; 20% in control). DLBCL samples had increased proportion of regulatory T-cells (Treg) compared to controls (16.9% vs. 6.5%), even after stratifying for tissue of origin (Figure 2). Multiparametric analysis of cytotoxic (CD8+) T-cell subsets revealed that majority of CD8+ T-cells in DLBCL has an effector memory (Tem) phenotype (81.9%) compared to tissue-matched control (43%). PD-1 expression was present in the majority of CD8+ T-cells and mapped to the Effector Memory and Effector subsets. The majority of PD-1 positive cells co-expressed CD27 (>80%). One of the samples (DLBCL arising in the spleen from CLL background) also demonstrated bright PD-1 expression in B-cells (Figure 3). CONCLUSIONS Mass cytometry reveals that the tumor microenvironment of DLBCL is enriched with CD4+ T-cells including a higher proportion of Treg compared to tissue-matched control. We also demonstrated that most cytotoxic T-cells in the TME of DLBCL have an effector memory phenotype and express other markers of activation and prior antigenic exposure. Co-expression of PD-1 and CD27 was common in CD8+ T-cells, providing rationale for studies of combination immunotherapy. PD-1 expression in B-cells of DLBCL arising from CLL background deserves further investigation. Figure 1 Proportion of major immune subsets found in the TME of DLBCL (blue) and control tissue (red). Figure 1. Proportion of major immune subsets found in the TME of DLBCL (blue) and control tissue (red). Figure 2 Proportion of regulatory T-cells (Treg) found in the TME of DLBCL (blue) compared to control (red). Bars represent standard error. Figure 2. Proportion of regulatory T-cells (Treg) found in the TME of DLBCL (blue) compared to control (red). Bars represent standard error. Figure 3 viSNE map of CD45+ cells from a patient with DLBCL arising from a CLL background. Each unit on the dot plot represents a cell. Their coordinates on the map are functions of their phenotypic distance. Major subsets were identified using unbiased clustering and annotated (A). Events were color coded according to the expression of representative markers (B-G). A heat map (H) displays median intensity of expression of a comprehensive set of markers included in the panel for each immune subset. Figure 3. viSNE map of CD45+ cells from a patient with DLBCL arising from a CLL background. Each unit on the dot plot represents a cell. Their coordinates on the map are functions of their phenotypic distance. Major subsets were identified using unbiased clustering and annotated (A). Events were color coded according to the expression of representative markers (B-G). A heat map (H) displays median intensity of expression of a comprehensive set of markers included in the panel for each immune subset. Disclosures Ansell: BMS, Seattle Genetics, Merck, Celldex and Affimed: Research Funding.


2013 ◽  
Vol 4 ◽  
Author(s):  
Erkers Tom ◽  
Nava Silvia ◽  
Yosef Jena ◽  
Ringd�n Olle ◽  
Kaipe Helen

2018 ◽  
Vol 3 (30) ◽  
pp. eaau2042 ◽  
Author(s):  
Kelly A. Remedios ◽  
Bahar Zirak ◽  
Priscila Munoz Sandoval ◽  
Margaret M. Lowe ◽  
Devi Boda ◽  
...  

Regulatory T cells (Tregs) are closely related to TH17 cells and use aspects of the TH17-differentiation program for optimal immune regulation. In several chronic inflammatory human diseases, Tregs express IL-17A, suggesting that dysregulation of TH17-associated pathways in Tregs may result in either loss of suppressive function and/or conversion into pathogenic cells. The pathways that regulate the TH17 program in Tregs are poorly understood. We have identified two TNF receptor superfamily (TNFRSF) members, CD27 and OX40, that are preferentially expressed by skin-resident Tregs. Both CD27 and OX40 signaling suppressed the expression of TH17-associated genes from Tregs in a cell-intrinsic manner in vitro and in vivo. However, only OX40 played a nonredundant role in promoting Treg accumulation. Tregs that lacked both CD27 and OX40 were defective in controlling skin inflammation and expressed high levels of IL-17A, as well as the master TH17 transcription factor, RORγt. Last, we found that CD27 expression was inversely correlated with Treg IL-17 production in skin of patients with psoriasis and hidradenitis suppurativa. Together, our results suggest that TNFRSF members play both redundant and distinct roles in regulating Treg plasticity in tissues.


Cytotherapy ◽  
2014 ◽  
Vol 16 (4) ◽  
pp. S28-S29
Author(s):  
A. Foussat ◽  
R. Rietze ◽  
M. Thompson ◽  
B. Schryver ◽  
R. Ehrhardt

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 2582-2582
Author(s):  
Rachel E Protheroe ◽  
Graziella Mazza ◽  
Kirsty S Nicolson ◽  
Colin G Steward ◽  
David C Wraith

Abstract There is extensive evidence from murine models supporting a role for CD4+CD25+ regulatory T cells in suppressing alloreactivity. However, clinical evidence regarding the role of regulatory T cells in human alloresponses is conflicting and may reflect the difficulty in defining and isolating naturally occurring human CD4+CD25+ regulatory T cells. Moreover, the mechanism of action of Foxp3+ regulatory T cells remains somewhat controversial with a number of proposed modes of suppression described, including cell contact-dependent inhibition, cytokine mediated suppression and cytokine consumption. We have previously used peripheral blood monocyte-derived dendritic cells (DCs) as antigen presenting cells (APCs) in allogeneic mixed lymphocyte reactions (MDCLRs), to assess the in vitro suppressive function of human CD4+CD25+ T cells. Healthy volunteer donor MACS isolated CD4+CD25+ regulatory T cells demonstrated anergy and significant dose-dependent suppression of responder cell proliferation, to physiological frequencies, in allogeneic MDCLRs (p<0.005). In this study we investigated the in vitro mechanism of action of human CD4+CD25+ T cells in suppressing alloreactivity in MDCLRs. Co-culture of CD4+CD25+ regulatory T cells with autologous CD4+ responder cells in allogeneic MDCLRs, at a ratio of 1:4, resulted in suppression of proliferation by 68%. Peak suppression of CD4+ responder cell proliferation, observed on day five of co-culture, was accompanied by significant suppression of co-culture supernatant IL-5 concentration (p<0.05), and preceded by inhibition of IL-2. Intracellular cytokine staining confirmed that CD4+ responder cell intracellular IL-2 was reduced by 60% on co-culturing with CD4+CD25+ regulatory T cells in the allogeneic MDCLR. CD4+CD25+ regulatory T cells mediated suppression of proliferation and cytokine responses across transwell membranes, demonstrating a cell contact-independent mechanism and a potential soluble factor in the mode of action of CD4+CD25+ regulatory T cells in suppressing human alloresponses. This was confirmed by suppression of responder cell proliferation and cytokine responses by supernatant transfer from DCs co-cultured with allogeneic CD4+CD25+ regulatory cells. We surveyed possible candidate molecules responsible for mediating the cell contact-independent suppression; in our hands, neither IL-10 nor TGF-β was identified as the soluble factor. Next, we examined the effect of CD4+CD25+ regulatory T cells on APCs in the allogeneic MDCLR. Immunophenotypic characterization of DCs recovered from MDCLRs in the presence of CD4+CD25+ regulatory T cells showed down-regulation of HLA-DR, CD83, and co-stimulatory molecules, CD80 and CD86, compared with DCs cultured with CD4+CD25− T cells or cytokines, IL-4 and GM-CSF, alone. The suppression of DC activation by CD4+CD25+ regulatory T cells was not mediated across transwell membranes, demonstrating a cell contact-requirement. Moreover, downregulation of DC activation markers was not accompanied by IL-12 suppression, implying no role for IL-10 in mediating the suppressive effect of the regulatory cells on the APCs. Our results demonstrate both a cell contact-independent mode of action in suppressing CD4+ responder cell proliferation, Th1 and Th2 cytokine responses, independent of IL-10 and TGF-β, and a cell contact-requirement in the suppression of allogeneic DC maturation and activation. In summary, our findings suggest that multiple mechanisms of action contribute to the in vitro suppressive effects of human CD4+CD25+ regulatory T cells on alloreactivity.


2021 ◽  
Author(s):  
Rebecca Harris ◽  
Mahinbanu Mammadli ◽  
Mobin Karimi

AbstractRegulatory T cells (Tregs) are suppressive immune cells used for a variety of clinical and therapeutic applications. Canonical Tregs express CD4, FOXP3, and CD25, which are considered definitive markers of Treg status when used together. However, a subset of noncanonical Tregs expressing only CD4 and FOXP3 have recently been described in some infection contexts. The transcriptional regulation of these cells is still unclear. We found that loss of TCF-1 in all T cells in mice leads to expansion of these cells in multiple tissues in a cell-intrinsic fashion. This effect was not due to aberrant expression of FOXP3, as other functional Treg markers were also expressed. In addition, presence of TCF-1-deficient cells in a chimeric mouse induced increased production of noncanonical Tregs from WT donor cells. Therefore, targeting of TCF-1 may remove suppression on this Treg lineage, increasing the yield of these cells for use in the clinic.Summary sentenceLoss of TCF-1 causes expansion of CD25- FOXP3+ noncanonical Tregs, and TCF-1-deficient T cells induce increased production of CD25- Tregs from WT cells.


Sign in / Sign up

Export Citation Format

Share Document